LFM-A13(Z)

CAS No.	244240-24-2	Cat. No.	BCP12817
Name	LFM-A13(Z)
Synonyms	LFMA13;LFM A13;(Z)-2-Cyano-N-(2,5-dibromophenyl)-3-hydroxybut-2-enamide;
Formula	C11H8Br2N2O2	M. Wt	360

Description	in vitro: LFM-A13 inhibited recombinant BTK expressed in a baculovirus expression vector system with an IC50 value of 2.5 microM. Even at concentrations as high as 100 micrograms/ml (approximately 278 microM), this novel inhibitor did not affect the enzymatic activity of other protein tyrosine kinases, including JAK1, JAK3, HCK, epidermal growth factor receptor kinase, and insulin receptor kinase. Inhibition of Btk activity by LFM-A13 leads to enhancement of PKCtheta; activity, whereas nonselective inhibition of PKC activity by bisindolylmaleimide I leads to reduction in Btk activity. in vivo: LFM-A13 suppressed migration and differentiation of osteoclast precursors as well as bone-resorbing activity of mature osteoclasts. In primary myeloma-bearing SCID-rab mice, LFM-A13 inhibited osteoclast activity, prevented myeloma-induced bone resorption and moderately suppressed myeloma growth.
Pathways	Angiogenesis/Protein Tyrosine Kinase Cell Cycle/DNA Damage Jak/Stat Pathway Wnt/Stem Cell Epigenetics
Targets	JAK BTK PLK

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.

For product details of different batches, please contact our Customer

Products are for research use only and not for human use. We do not sell to patients.